An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Completed · Phase 1

Conditions studied: Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute

In brief

This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296). Participants are eligible to participate in this study if they have completed required Phase 1 study assessments for primary objectives of respective parent protocol and are having evidence of clinical benefit (as defined by the parent protocol). Participants will continue the most similar dose and formulation available (which does not exceed the maximum tolerated dose \[MTD\] or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from the parent clinical study protocol.

Key facts

Study ID

NCT01677780

Run by

Hoffmann-La Roche

People needed

11

Starts

2012-11-28

Expected to finish

2017-06-26

Last updated by the study team

2017-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must meet the inclusion criteria outlined in the respective parent protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296)
• Participants must have completed one of the following clinical study protocols and have been determined to have clinical benefit on treatment at the conclusion of required study analyses as defined in the respective parent protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296)

You may not qualify if…

• Participants must meet the exclusion criteria outlined in the respective parent protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296)
• Participants who developed disease progression/ requiring other anti-tumor therapy while in the parent protocol
• Participants who have stopped study drug dosing for greater than 56 days
• Participants continuing to require dose modifications
• Participants with worsening adverse events
• Participants with unrelated adverse events, medical illnesses, or changes in performance status that, per investigator discretion, put them at high risk for continuing participation in the clinical study

Where it is running

• Sarcoma Oncology Center — Santa Monica, California, United States
• M.D Anderson Cancer Center; Oncology — Houston, Texas, United States
• Cancer Therapy & Research Ctr; Dept Institute for Drug Development — San Antonio, Texas, United States
• Princess Margaret Hospital, Medical Oncology & Haematology — Toronto, Ontario, Canada
• Institut Claudius Regaud; Departement Oncologie Medicale — Toulouse, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.